Literature DB >> 21755370

Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Kathleen Carey1, Babak Saboury, Sandip Basu, Alex Brothers, Alexis Ogdie, Tom Werner, Drew A Torigian, Abass Alavi.   

Abstract

Assessing joint disorders has been a relatively recent and evolving application of 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging. FDG is taken up by inflammatory cells, particularly when they are active as part of an ongoing inflammatory process. Hence FDG PET has been employed to assess a wide array of arthritic disorders. FDG PET imaging has been investigated in various joint diseases for diagnostic purposes, treatment monitoring, and as a prognostic indicator as in other disorders. In some of the diseases the ancillary findings in FDG PET have provided important clues about the underlying pathophysiology and pathogenesis processes. While substantial promise has been demonstrated in a number of studies, it is clear that the potential utility of PET in this clinical realm far outweighs that which has been established to date.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21755370     DOI： 10.1007/s00259-011-1863-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  70 in total

1.  Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch.

Authors:  D Blockmans; S Stroobants; A Maes; L Mortelmans
Journal:  Am J Med       Date:  2000-02-15       Impact factor: 4.965

2.  Arthritis of the large joints - in particular, the knee - at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis.

Authors:  S P Linn-Rasker; A H M van der Helm-van Mil; F C Breedveld; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2006-12-01       Impact factor: 19.103

3.  Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT.

Authors:  Ron S Rosen; Laura Fayad; Richard L Wahl
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

4.  F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis.

Authors:  Gerhard W Goerres; Adrian Forster; Daniel Uebelhart; Burkhardt Seifert; Valerie Treyer; Beat Michel; Gustav K von Schulthess; Achim H Kaim
Journal:  Clin Nucl Med       Date:  2006-07       Impact factor: 7.794

5.  Joint accumulations of FDG in whole body PET scans.

Authors:  G K von Schulthess; N Meier; K D Stumpe
Journal:  Nuklearmedizin       Date:  2001-12       Impact factor: 1.379

6.  Fluorine-18-fluorodeoxyglucose uptake in rheumatoid arthritis-associated lung disease in a patient with thyroid cancer.

Authors:  S M Bakheet; J Powe
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

Review 7.  Rheumatoid arthritis classification criteria - It's finally time to move on!

Authors:  Jeremy Sokolove; Vibeke Strand
Journal:  Bull NYU Hosp Jt Dis       Date:  2010

8.  Diffuse FDG shoulder uptake on PET is associated with clinical findings of osteoarthritis.

Authors:  Eric Wandler; Elissa L Kramer; Orrin Sherman; James Babb; Jean Scarola; Mahvash Rafii
Journal:  AJR Am J Roentgenol       Date:  2005-09       Impact factor: 3.959

9.  Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium.

Authors:  Anne Roivainen; Riitta Parkkola; Timo Yli-Kerttula; Pertti Lehikoinen; Tapio Viljanen; Timo Möttönen; Pirjo Nuutila; Heikki Minn
Journal:  Arthritis Rheum       Date:  2003-11

10.  Multiple extra-articular synovial cysts complicated with rheumatoid arthritis.

Authors:  Yohei Kirino; Atsushi Ihata; Kazuya Shizukuishi; Maasa Hama; Kaoru Takase; Akiko Suda; Atsuhisa Ueda; Shigeru Ohno; Mitsuhiro Takeno; Yoshiaki Ishigatsubo
Journal:  Mod Rheumatol       Date:  2009-06-13       Impact factor: 3.023
View more
  8 in total

Review 1.  Non-FDG PET in oncology.

Authors:  R Núñez Miller; M A Pozo
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

2.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 3.  Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease.

Authors:  Feliks Kogan; Audrey P Fan; Garry E Gold
Journal:  Quant Imaging Med Surg       Date:  2016-12

Review 4.  Applications of PET-Computed Tomography-Magnetic Resonance in the Management of Benign Musculoskeletal Disorders.

Authors:  James S Yoder; Feliks Kogan; Garry E Gold
Journal:  PET Clin       Date:  2019-01

5.  An update on the unparalleled impact of FDG-PET imaging on the day-to-day practice of medicine with emphasis on management of infectious/inflammatory disorders.

Authors:  Abass Alavi; Søren Hess; Thomas J Werner; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

Review 6.  Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis.

Authors:  James M Mountz; Abass Alavi; John D Mountz
Journal:  Nat Rev Rheumatol       Date:  2012-09-25       Impact factor: 20.543

7.  Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans.

Authors:  Molly A Parsons; Mateen Moghbel; Babak Saboury; Drew A Torigian; Thomas J Werner; Domenico Rubello; Sandip Basu; Abass Alavi
Journal:  Nucl Med Commun       Date:  2015-12       Impact factor: 1.690

8.  Semi-quantitative analysis of 18F fluorodeoxyglucose uptake in the assessment of disease activity and therapeutic response in rheumatoid arthritis: An institutional experience.

Authors:  Reddy Ravikanth; Jyotin Kshitiz Singh
Journal:  World J Nucl Med       Date:  2020-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.